Welcome to the Antimicrobial Chemotherapy Virtual Conference 2021

This conference is FREE OF CHARGE to attend

Register now

Jointly organised by the BSAC and GARDP. For 2021, the conference collaborators are the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), the German Center for Infection Research (DZIF) and the International Research Alliance for Antibiotic Discovery and Development (IRAADD) (a JPIAMR funded network)

HIPS logo

Programme

Please note: All timings below are GMT

 

1300
Introductory remarks
Professor Laura JV Piddock, Director of Scientific Affairs, Global Antibiotic Research & Development Partnership (GARDP) - View Bio

SESSION ONE: KEYNOTE PRESENTATION
Chair: Professor Laura JV Piddock, Director of Scientific Affairs, Global Antibiotic Research & Development Partnership (GARDP) - View Bio
1305
The politics of drug development
Dame Sally Davies, UK Government Special Envoy on Antimicrobial Resistance, UK Department of Health and Social Care - View Bio
1325
Q&A

1335
BREAK

SESSION TWO: Early Drug Discovery
Chair: Dr Marcus Miethke, Scientist & Project Manager, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) - View Bio
1345
In vitro and in vivo profiling of natural products from Myxobacteria towards the development of anti-infective drugs
Dr Jennifer Herrmann, Scientist, HIPS/HZI & DZIF - View Bio
1400
Gram-negative antibacterial discovery - looking for the high-hanging fruits
Dr Benjamin Blasco Discovery Senior Project Manager, GARDP - View Bio
1415
Microbial natural products: still an untapped source for novel antibiotic discovery
Dr Olga Genilloud, Scientific Director, Fundación MEDINA - View Bio
1430
Q&A
All speakers

1440
BREAK

SESSION THREE: Pre-clinical antimicrobial development
Chair: Professor Alasdair MacGowan, Consultant in Infection at North Bristol NHS Trust & Professor of Antimicrobial Therapeutics at the University of Bristol - View Bio
1450
From old drugs to new: Repurposing old antibiotics to combat antimicrobial resistance
Dr Christopher Darlow, MRC Clinical Research Fellow, Institute of Systems, Molecular & Integrative Biology, University of Liverpool - View Bio
1505
Linking PK and PD studies in animals with PBPK/PD modelling – in silico from mouse to human
Dr Katharina Rox, Postdoc, HZI/DZIF - View Bio
1520
Pre-clinical development of Corallopyronin A – a novel natural product active against helminths, STIs and Staphylococci
Professor Achim Hoerauf, Institute of Medical Microbiology, Immunology and Parasitology, University Hospital Bonn/DZIF - View Bio
1535
Q&A
All speakers

1545
BREAK

SESSION FOUR: POSTER SESSION
Chair: Prof Dr Rolf Müller, Head of Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS) & Department Microbial Natural Products (MINS), Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS) - View Bio
1555 - 1630
6 posters will be presented followed by Q&A

1630
Day one closing remarks
Professor William Hope, University of Liverpool - View Bio
1300
Introductory remarks
Professor William Hope, University of Liverpool - View Bio

SESSION FIVE: Learning lessons: clinical trials
Chair: Professor Mike Sharland, Consultant in paediatric infectious diseases, St George's University Hospitals NHS Foundation Trust - View Bio
1305
Lessons for Clinical Research from COVID-19
Professor Andy Ustianowski, Principal Clinical Research Lead, North Manchester General Hospital - View Bio
1320
Innovative design of clinical trials
Professor Sarah Walker, University College London - View Bio
1335
Developing a TB drug in academia: The BTZ043 from lead candidate to pivotal clinical trials – lesson learned from a complex endeavour
Michael Hölscher, LMU Munich, Germany
1350
Q&A
All speakers

1400
BREAK

SESSION SIX: Non-traditional approaches and challenges
Chair: Ursula Theuretzbacher, Founder, Center for Anti-Infective Agents (CEFAIA) - View Bio
1410
The non-traditional treatment pipeline
Ursula Theuretzbacher, Founder, Center for Anti-Infective Agents (CEFAIA) - View Bio
1425
Elastase inhibitor
Dr Martin Everett, Chief Scientific Officer, Antabio - View Bio
1440
Therapeutic Development of Bacteriophages
Professor Martha Clokie, Professor of Microbiology, University of Leicester - View Bio
1455
Q&A
All speakers

1505
BREAK

SESSION SEVEN: KEYNOTE PRESENTATION
Chair: Dr Jean-Pierre Paccaud, Director, Business Development and Corporate Strategy, Global Antibiotic R&D Partnership (GARDP) - View Bio
1515
Science vs. Finance: The realities of antibacterial drug research and development
Dr Patricia Bradford, Owner, Antimicrobial Development Specialists, LLC - View Bio
1535
Q&A

1545
BREAK

SESSION EIGHT: PANEL DISCUSSION
Chair: Professor Laura JV Piddock, Director of Scientific Affairs, Global Antibiotic Research & Development Partnership (GARDP) - View Bio
1555-1700
Careers in Drug Development and Antimicrobial Chemotherapy
Dr Olga Genilloud, Scientific Director, Fundación MEDINA - View Bio
Sumati Nambiar, Director, Division of Anti-Infective (DAI), FDA - View Bio
Prof Dr Rolf Müller, Head of Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS) & Department Microbial Natural Products (MINS), Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS) - View Bio
Dr Martin Everett, Chief Scientific Officer, Antabio - View Bio

1700
Closing remarks
Professor Laura Piddock, Director of Scientific Affairs, GARDP - View Bio

Abstracts

Please note that abstract submissions for this virtual conference has now closed.

Registration

We encourage you to register, submit abstracts and join us in what promises to be another innovative and exciting conference.

Registration is free of charge. For queries regarding registration, please contact Esme Carruthers at Ecarruthers@bsac.org.uk

Due to restrictions around COVID-19 this conference will be fully virtual.

Please note that any information you provide may be shared with GARDP Foundation and our other conference partners.

REGISTER NOW

Having trouble finding what you're after?

Top